This inventor holds 10 USPTO granted patents and 2 EPO patents. Top assignees: Array Biopharma Inc., Mirati Therapeutics, Inc.. Active years: 2022-2026.
Location History:
- Boulder, CO (US) (2022 - 2023)
- Superior, CO (US) (2022 - 2024)
- Indianapolis, IN (US) (2024)
Company Filing History:
10 out of 333 
6 out of 44 
Years Active: 2022-2026
Title: The Innovative Contributions of Donghua Dai
Introduction
Donghua Dai is a prominent inventor based in Superior, Colorado, known for his significant contributions to the field of pharmaceutical sciences. With a total of 10 patents, he has made remarkable strides in developing compounds that target critical pathways in cancer treatment.
Latest Patents
Among his latest patents are the development of fused heterocyclic compounds as RET kinase inhibitors. These compounds are designed to inhibit RET kinase, which is crucial in treating RET-associated diseases and disorders. Another notable patent involves KRas G12D inhibitors, which focus on compounds that inhibit the activity of KRas G12D, a significant target in cancer therapy. These compounds are accompanied by pharmaceutical compositions and methods for their use in treating cancer.
Career Highlights
Donghua Dai has worked with several notable companies in the pharmaceutical industry, including Array Biopharma Inc. and Mirati Therapeutics, Inc. His work has been instrumental in advancing therapeutic options for patients suffering from various forms of cancer.
Collaborations
Throughout his career, Donghua has collaborated with esteemed colleagues, including James F. Blake and Dean Russell Kahn. These partnerships have fostered innovation and contributed to the development of groundbreaking therapies.
Conclusion
Donghua Dai's innovative work in the field of pharmaceuticals highlights his commitment to advancing cancer treatment through targeted therapies. His contributions continue to impact the medical community and improve patient outcomes.